| abstract |
The invention relates to methods of selecting a subject, and methods of treating the subject with an anti-VLA-l antibody. In one embodiment the first therapeutic agent is a DMARD (Disease Modifying Antirheumatic Drug), such as gold salts; hydroxychloroquine; an antifolate, such as methotrexate; a pynmidine synthesis inhibitor, such as leflunomide; or a sulfa drug, such as sulfasalazine. For example, the DMARD can be methotrexate, administered at a dose of mg/week or less; leflunomide, administered at a dose of 20 mg/day or less; sulfasalazine, administered at a dose of 3000 mg/day or less; or hydroxychloroquine, administered at a dose of 400 mg/day or less. |